Recent trends in Molecular Imaging : PET/CT in Neurology
<div><div>PET/CT is an important molecular imaging technique for the assessment of</div><div>neurological disorders. The most widely used radiopharmaceutical for both clinical and research purposes is [18F] 2-fluoro-2-deoxy-D-glucose (FDG). It is extensively used owing to its...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2015-06-01
|
| Series: | Annals of the National Academy of Medical Sciences (India) |
| Subjects: | |
| Online Access: | http://annals-nams.in/index.php/annals/article/view/80 |
| Summary: | <div><div>PET/CT is an important molecular imaging technique for the assessment of</div><div>neurological disorders. The most widely used radiopharmaceutical for both clinical and research purposes is [18F] 2-fluoro-2-deoxy-D-glucose (FDG). It is extensively used owing to its favourable physical characteristics. It enables depiction of cerebral glucose metabolism, and has thus been used to study various pathological states. Despite this, FDG has its own limitations. This is owing to its limited specificity and high cortical uptake. This has paved the way for the development of several non-FDG PET radiopharmaceuticals. We present the insights gained at our institution, using these radiotracers in the assessment of neurological disease. Our study shows that the use of FDG and non-FDG novel PET radiopharmaceuticals facilitates the early diagnosis, delineation of extent, prognostication and monitoring of therapeutic response in several neuropathological states.</div></div>PET/CT is an important molecular imaging technique for the assessment ofneurological disorders. The most widely used radiopharmaceutical for both clinicaland research purposes is [18F] 2-fluoro-2-deoxy-D-glucose (FDG). It is extensivelyused owing to its favourable physical characteristics. It enables depiction of cerebralglucose metabolism, and has thus been used to study various pathological states.Despite this, FDG has its own limitations. This is owing to its limited specificity andhigh cortical uptake. This has paved the way for the development of several non-FDGPET radiopharmaceuticals. We present the insights gained at our institution, usingthese radiotracers in the assessment of neurological disease. Our study shows that theuse of FDG and non-FDG novel PET radiopharmaceuticals facilitates the earlydiagnosis, delineation of extent, prognostication and monitoring of therapeuticresponse in several neuropathological states. |
|---|---|
| ISSN: | 0379-038X 2454-5635 |